Aetna Wun Trombley, Lycia CEO
September 9, 2021 07:00 AM EDTUpdated September 10, 02:21 PM
Financing

Eli Lil­ly-backed Ly­cia fu­els up on VC cash in a dis­cov­ery dri­ve to­ward pro­tein degra­da­tion 2.0

Paul Schloesser

Associate Editor

Just weeks af­ter nab­bing a mar­quee al­liance with Eli Lil­ly, the phar­ma gi­ant has come back to sup­port a $70 mil­lion B round for Ly­cia Ther­a­peu­tics de­signed to fund the next stage of dis­cov­ery at the pro­tein degra­da­tion play­er.

Founder Ver­sant Ven­tures al­so came back to add to the round, join­ing new in­vestors Red­mile Group, Cowen Health­care In­vest­ments, In­vus, RTW In­vest­ments, LP, Eli Lil­ly and Alexan­dria.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In lat­est turn to au­toim­mune ther­a­pies, Cul­li­nan nabs $280M to join lu­pus space

Take­da’s new deal with Kumquat; IL-2 biotech rais­es $55M

Ab­b­Vie inks deal for Med­in­cell's long-act­ing in­jectable plat­form worth up to $1.9B

FDA is ready to elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars

Boehringer In­gel­heim touts 10-year plan as it eyes over­tak­ing Bay­er as Ger­many’s largest phar­ma

No­var­tis show­cas­es Ph3 da­ta for Fab­hal­ta in IgAN as FDA grants pri­or­i­ty re­view

A service from the Financial Times